New treatment against transplantation complications tested – Medical News Today

Last updated: 4 September 2014 at 2am PST A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function It is not uncommon for kidney transplants to fail. Once transplanted, the kidney must connect back with the blood supply to Read more about New treatment against transplantation complications tested – Medical News Today[…]

Tocilizumab Research Could Lead to Personalized Treatments for Kidney Transplant Patients

Eileen Oldfield, Associate Editor Published Online: Saturday, August 9, 2014 A multicenter study will examine whether a drug used to treat rheumatoid arthritis can improve kidney transplant patients’ health. Researchers from several medical centers will use rheumatoid arthritis drug tocilizumab in a study to determine whether the drug improves kidney transplant patients’ long-term survival. The Read more about Tocilizumab Research Could Lead to Personalized Treatments for Kidney Transplant Patients[…]

Company agrees to $35-million settlement over kidney transplant – 21 News Now, More Local News for Youngstown, Ohio –

Company agrees to $35-million settlement over kidney transplant drug Posted: Aug 06, 2014 9:34 AM Updated: Aug 06, 2014 9:42 AM COLUMBUS, Ohio – Ohio Attorney General Mike DeWine has announced that Ohio and 41 other attorneys general have reached a $35 million settlement to resolve allegations that Wyeth Pharmaceuticals Inc. unlawfully promoted Rapamune, a drug Read more about Company agrees to $35-million settlement over kidney transplant – 21 News Now, More Local News for Youngstown, Ohio –[…]

Protein May Prevent Antibody-Mediated Transplant Rejection

Thu, 07/31/2014 – 8:40am A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring’s C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system. The study shows that post-transplant treatment Read more about Protein May Prevent Antibody-Mediated Transplant Rejection[…]